# Parabilis Sets Oct. 24 ESMO Presentation for Zolucatetide Data

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/35089
Published: 2026-10-19T22:50:44.000Z
Updated: 2026-10-19T22:50:44.000Z
Section: Business

> The update covers data through June 22 from an ongoing Phase 1/2 study. Dose-optimization results are intended to help select a dose and schedule for a planned Phase 3 desmoid tumor trial.

Parabilis Medicines will present updated Phase 1/2 zolucatetide data at the Oct. 24 European Society for Medical Oncology Congress, with dose-optimization findings intended to help select dosing for a planned Phase 3 desmoid tumor trial.

The results reflect a June 22 data cutoff and span both the study’s dose-escalation and dose-optimization stages. The dose-optimization findings are intended to help determine a dose and treatment schedule for the planned Phase 3 study.

The presentation is part of a sarcoma session scheduled for 8:45 to 10:15 a.m. ET (12:45 to 14:15 UTC) in Madrid. Parabilis also plans to host an investor webcast about the data at noon ET (16:00 UTC).

Zolucatetide is an investigational drug designed to disrupt the interaction between β-catenin and T-cell factor, which is linked to desmoid tumor biology. Desmoid tumors are connective-tissue growths that can invade nearby soft tissue.